Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (28478)	3/5/1999 4:29:00 PM
From: J Stone	Respond to of 32384

Given LGND's performance over the past year and a half, you shouldn't be surprised at it's fall today. LGND seems to have a negative correlation with the DOW.

To: RXGOLF who wrote (28478)	3/6/1999 8:26:00 PM
From: smh	Read Replies (1) \| Respond to of 32384

From the Kiplinger Washington Letter; <...promising new approach to preventing cancer. "Chemoprevention" drugs....designed to thwart cell changes that lead to malignancies. ...tamoxifene by Zeneca, works against breast cancer, but serious side effects limit its use only to women in high risk groups. Raloxifene from Eli Lilly promises to have fewer side effects in fighting breast cancer. Originally approved for use in osteoporosis, it will be tested in a breast cancer prevention trial starting this year. Finasteride from Merck for prevention of prostate cancer... Other drugs in studies: Serm III from Eli Lilly. Idoxifene from SmithKline Beecham. Droloxifene by Pfizer. All for breast cancer.>